SALT LAKE CITY, Jan. 25, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced that a presentation entitled: “Extensive 5-FU Inter-Patient Pharmacokinetic Variability May Result in Suboptimal 5-FU Dosing of Metastatic and Adjuvant Colon Cancer Patients on FOLFOX Regimens,” was presented on Sunday, January 24th, 2010, at the Seventh Annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. 5-fluorouracil (5-FU) is a backbone of many chemotherapy regimens, including FOLFOX (folinic acid, fluorouracil and oxaliplatin), FOLFOX6, and FOLFIRI (folinic acid, fluorouracil and irinotecan), and is used extensively in the treatment of colorectal, metastatic breast, and head and neck cancers.
